Morepen Laboratories has reported total income of Rs.388.31 crores during the period ended June 30, 2021 as compared to Rs.290.76 crores during the period ended March 31, 2021.

The company reported total income of Rs.258.97 crores during the period ended June 30, 2020.

The company has posted net profit of Rs.30.47 crores for the period ended June 30, 2021 as against net profit of Rs.26.76 crores for the period ended March 31, 2021.

Morepen Laboratories has posted net profit of Rs.30.47 crores for the period ended June 30, 2021 as against net profit of Rs.19.36 crores for the period ended June 30, 2020.

Sushil Suri, Managing Director and Chairman stated, "Our partnership with RDIF to manufacture Sputnik vaccine in India is a big milestone for the company. We have a capacity to manufacture up to 250 million dose per annum that can be ramped up to 500 million doses per annum. We remain committed to fight the battle of Covid and gear ourselves for fast vaccination of the nation. Morepen's commitment towards this project is step forward towards entry into biosimilars and other biologicals."